Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
Dermatomyositis (DM) is one of the uncommon multi-organ idiopathic inflammatory myopathies that has been reported following the hepatitis B, Influenza, tetanus toxoid, H1N1, and BCG vaccines. However, an association with the coronavirus disease 2019 (COVID-19) vaccine is yet to be reported. In this...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822116/ https://www.ncbi.nlm.nih.gov/pubmed/35132838 http://dx.doi.org/10.3346/jkms.2022.37.e32 |
_version_ | 1784646545433427968 |
---|---|
author | Gouda, Wesam Albasri, Anwar Alsaqabi, Faisal Al Sabah, Humoud Y. Alkandari, Marwan Abdelnaby, Hassan |
author_facet | Gouda, Wesam Albasri, Anwar Alsaqabi, Faisal Al Sabah, Humoud Y. Alkandari, Marwan Abdelnaby, Hassan |
author_sort | Gouda, Wesam |
collection | PubMed |
description | Dermatomyositis (DM) is one of the uncommon multi-organ idiopathic inflammatory myopathies that has been reported following the hepatitis B, Influenza, tetanus toxoid, H1N1, and BCG vaccines. However, an association with the coronavirus disease 2019 (COVID-19) vaccine is yet to be reported. In this case, we present the case of a 43-year-old Asian Indian female who was diagnosed with DM 10 days after receiving the second dosage of BNT162b2 mRNA COVID-19 vaccination, in the absence of any additional triggering factors. The diagnosis was established based on physical examination, serological antibodies, magnetic resonance imaging of the muscles, skin biopsy, and electromyography. She received standard treatment for DM, including oral high doses of prednisolone, hydroxychloroquine, mycophenolate, and physiotherapy. The treatment successfully reversed skin changes and muscle weakness. This is the first reported case of classic DM complicated by interstitial lung disease following COVID-19 vaccination. More clinical and functional studies are needed to elucidate this association. Clinicians should be aware of this unexpected adverse event following COVID-19 vaccination and arrange for appropriate management. |
format | Online Article Text |
id | pubmed-8822116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-88221162022-02-15 Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination Gouda, Wesam Albasri, Anwar Alsaqabi, Faisal Al Sabah, Humoud Y. Alkandari, Marwan Abdelnaby, Hassan J Korean Med Sci Case Report Dermatomyositis (DM) is one of the uncommon multi-organ idiopathic inflammatory myopathies that has been reported following the hepatitis B, Influenza, tetanus toxoid, H1N1, and BCG vaccines. However, an association with the coronavirus disease 2019 (COVID-19) vaccine is yet to be reported. In this case, we present the case of a 43-year-old Asian Indian female who was diagnosed with DM 10 days after receiving the second dosage of BNT162b2 mRNA COVID-19 vaccination, in the absence of any additional triggering factors. The diagnosis was established based on physical examination, serological antibodies, magnetic resonance imaging of the muscles, skin biopsy, and electromyography. She received standard treatment for DM, including oral high doses of prednisolone, hydroxychloroquine, mycophenolate, and physiotherapy. The treatment successfully reversed skin changes and muscle weakness. This is the first reported case of classic DM complicated by interstitial lung disease following COVID-19 vaccination. More clinical and functional studies are needed to elucidate this association. Clinicians should be aware of this unexpected adverse event following COVID-19 vaccination and arrange for appropriate management. The Korean Academy of Medical Sciences 2022-01-07 /pmc/articles/PMC8822116/ /pubmed/35132838 http://dx.doi.org/10.3346/jkms.2022.37.e32 Text en © 2022 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Gouda, Wesam Albasri, Anwar Alsaqabi, Faisal Al Sabah, Humoud Y. Alkandari, Marwan Abdelnaby, Hassan Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination |
title | Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination |
title_full | Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination |
title_fullStr | Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination |
title_full_unstemmed | Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination |
title_short | Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination |
title_sort | dermatomyositis following bnt162b2 mrna covid-19 vaccination |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822116/ https://www.ncbi.nlm.nih.gov/pubmed/35132838 http://dx.doi.org/10.3346/jkms.2022.37.e32 |
work_keys_str_mv | AT goudawesam dermatomyositisfollowingbnt162b2mrnacovid19vaccination AT albasrianwar dermatomyositisfollowingbnt162b2mrnacovid19vaccination AT alsaqabifaisal dermatomyositisfollowingbnt162b2mrnacovid19vaccination AT alsabahhumoudy dermatomyositisfollowingbnt162b2mrnacovid19vaccination AT alkandarimarwan dermatomyositisfollowingbnt162b2mrnacovid19vaccination AT abdelnabyhassan dermatomyositisfollowingbnt162b2mrnacovid19vaccination |